Although there are no previous studies that have looked at the effect of tofacitinib or JAK inhibition on DM, the JAK–STAT pathway is implicated in both T1 and T2DM, which might explain the findings of our study. The gene discussed is SOAT1; the disease is type 2 diabetes mellitus.